Breast Cancer Topo Ⅱ α Gene Amplification Research Correlation With Clinical Pathological Features And Clinical Significance Of Detection

Objective:To investigate the relationship between Topo Ⅱα gene amplification,anthracycline drugs’s chemotherapy sensitivity, Her-2gene amplification, molecular typing in breast cancer, Topo Ⅱ aprotein expression and the pathological grade, to observe whether Topo Ⅱα gene was a predictive factor of breast cancer with anthracycline chemotherapy regimens.Methods:Used to clinical follow-up of222cases of breast cancer modified radical surgery patients with anthracycline drugs programme adjuvant chemotherapy,by fluorescence in situ hybridization (FISH) to detect the expression of Topo Ⅱα gene in the postoperative specimens, according to their prognosis, to analyze the relationship between Topo Ⅱα gene amplification, the effect of chemotherapy, Her-2gene amplification, molecular typing in breast cancer, the Topo II aprotein expression and the pathological grade. All statistical analyses were performed using the SPSS program for Windows (version13.0), using the chi-square test, P<0.05had statistical significance.Results:Topo Ⅱα gene amplification was33cases in222tissue samples. The total amplification rate of Topo Ⅱ agene was14.86%in222cases of breast cancer. Topo Ⅱα gene amplification was20cases in the endocrine treated group, the effective rate of chemotherapy was95%, Topo II a gene not amplified in120cases, the effective rate of chemotherapy was71.7%. Topo Ⅱα gene amplification was12cases in the endocrine untreated group, the effective rate of chemotherapy was92%, Topo Ⅱ agene not amplified in69cases, the effective rate of chemotherapy was58%.The effective rate of chemotherapy in Topo Ⅱα gene amplification group was significantly higher than another group.The24.11%Her-2gene and Topo Ⅱα gene were synchronous amplification,75.89%Her-2gene was amplification,but Topo Ⅱα gene didn’t amplificate; No Her-2gene amplification in breast cancer tissues,6cases without Topo Ⅱα gene amplification; In222breast cancer patients, ER (+)115cases, ER (-)107cases. PR (+)119cases, PR (-)103cases.Her-2(+)112cases, Her-2(-)110cases, the molecular type:Luminal A83cases, Luminal B53cases, Her-2overexpression63cases, three female23cases. The expression positive rate of Topo II a protein was54.05%in222cases, In the Topo Ⅱαprotein positive expression group, Topo Ⅱαgene amplification15.83%, no amplification84.17%; In the negative expression group, Topo II a gene amplification13.71%,86.29%no amplification.According to the WHO breast tumor histologic criteria, the222breast cancer cases were graded with pathology, including grade Ⅰ8cases, grade Ⅱ189cases, grade Ⅲ25cases.Topo Ⅱα gene amplification was33cases (grade Ⅰ lcases, grade Ⅱ29cases, grade Ⅲ3cases),189cases without amplification.Conclusion:Topo Ⅱα gene amplification has correlation with Her-2gene amplification (P<0.05).Different breast cancer molecular types had significant difference.Topo Ⅱα amplification occurred mainly in Her-2type and Luminal type B.A correlation was not found between the Topo Ⅱα gene amplification rate and the protein expression positive rate (P>0.05); Pathological grading and Topo II a gene amplification was not association (P>0.05). Topo Ⅱα gene amplification had significant difference with chemosensitivity of breast cancer to anthracyclines(P<0.05), after using anthracycline-based drugs treatment,patients with Topo Ⅱα gene amplification had higher survival rate and lower recurrence rate than no amplification patients.Topo Ⅱα gene was a predictive factor in breast cancer chemotherapy sensitivity of anthracycline drugs.